DV+BCG in HER2-Expressing, BCG-Nave High-Risk NMIBC
Status:
NOT_YET_RECRUITING
Trial end date:
2030-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk. Each participant was assigned to one of two study treatment groups: One group is given Disitamab Vedotin and BCG.The second group is given BCG only and will not receive Disitamab Vedotin.
Phase:
PHASE3
Details
Lead Sponsor:
Fudan University
Collaborators:
Fujian Cancer Hospital Ningbo Medical Center Li Huili Hospital Tenth People's Hospital of Tongji Univeristy Xinhua Hospital, Shanghai Jiao Tong University School of Medicine